Table 2.
Demographics and clinical characteristics of NYULH-EHR patients with type 2 diabetes
| Demographics and clinical characteristics | No. of patients [N = 16,665] |
|---|---|
| Age, years [mean (SD)] | 65.62 (13.66) |
| Male [n (%)] | 6876 (45.37) |
| Race [n (%)] | |
| African American | 5146 (33.96) |
| Native American | 55 (0.36) |
| Asian | 692 (4.57) |
| Caucasian (White) | 7888 (52.05) |
| Smoker, ever and current [n (%)] | 1043 (6.88) |
| Systolic blood pressure, mmHg [mean (SD)] | 128.93 (14.60) |
| Diastolic blood pressure, mmHg [mean (SD)] | 74.19 (8.88) |
| Body mass index, kg/m2 [mean (SD)] | 31.56 (6.86) |
| Triglycerides, mg/dL [mean (SD)] | 155.06 (91.97) |
| Creatinine, mg/dL [mean (SD)] | 1.02 (0.44) |
| Total cholesterol, mg/dL [mean (SD)] | 173.37 (39.82) |
| Low-density lipoproteins, mg/dL [mean (SD)] | 91.99 (33.53) |
| High-density lipoproteins, mg/dL [mean (SD)] | 51.00 (15.25) |
| A1c, % [mean (SD)] | 7.11 (1.46) |
| Medications | No. of patient encounters (n = 1,278,785) |
|---|---|
| Antihyperglycemic class [n (%)] | 665,768 |
| Biguanide type (BIG) | 250,438 (37.62) |
| Insulin-release stimulant type (INSR) | 110,139 (16.54) |
| Insulins (INSO) | 106,356 (15.97) |
| DPP-4 inhibitors (DPP4) | 64,090 (9.63) |
| DPP-4 inhibitor and biguanide (DPP4-BIG) | 53,337 (8.01) |
| Incretin mimetic (GLP-1 receptor agonist; GLP1) | 35,696 (5.36) |
| Sodium-glucose cotransporter-2 inhibitors (SGLT2) | 23,021 (3.46) |
| PPAR agonist thiazolidinedione (PPARg) | 12,573 (1.89) |
| Insulin-release stimulant and biguanide (INSR-BIG) | 10,118 (1.52) |
| Antihypertensive class [n (%)] | 849,328 |
| β-adrenergic blocking agents (BAB) | 200,114 (23.56) |
| Calcium channel blocking agents (CCB) | 151,701 (17.86) |
| ACE inhibitors (ACE) | 149,561 (17.61) |
| Angiotensin receptor antagonists (ARA) | 138,705 (16.33) |
| Angiotensin receptor antagonists with thiazide diuretic (ARA-TD) | 67,964 (8.00) |
| α/β-adrenergic blocking agents (ABAB) | 57,426 (6.76) |
| Thiazide and related diuretics (TD) | 57,196 (6.73) |
| ACE inhibitor with thiazide or thiazide-like diuretic (ACE-TD) | 14,486 (1.71) |
| Potassium-sparing diuretics in combination (PSD) | 6246 (0.74) |
| Angiotensin receptor antagonists with calcium channel blocking agents (ARA-CCB) | 5929 (0.70) |
| Lipid-lowering class [n (%)] | 428,427 |
| HMG-CoA reductase inhibitors (HMG) | 379,924 (88.68) |
| Lipotropics (LIP) | 40,173 (9.38) |
| Bile salt sequestrants (BSS) | 5262 (1.23) |
| HMG-CoA reductase inhibitors and cholesterol absorption inhibitors (HMG-CA) | 2286 (0.53) |
| Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9) | 782 (0.18) |
Categorical variables are expressed as frequency (%) unless otherwise indicated, and continuous variables are expressed as the mean (SD) of biomarkers
NYULH-EHR New York University Langone Health electronic health record, SD standard deviation, DPP-4 dipeptidyl peptidase-4, GLP-1 glucagon-like peptide 1, PPAR peroxisome proliferator-activated receptor, ACE angiotensin-converting enzyme